METHOD FOR PREDICTION OF CHLORPROMAZINE THERAPY EFFECTIVENESS EVALUATION FOR TREATING DISORDERS ACCOMPANYING DEVELOPMENT OF PSYCHOTIC SYMPTOMS Russian patent published in 2019 - IPC A61K31/54 G01N33/48 C12Q1/6827 A61P25/18 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to pharmacogenetics, and can be used for selecting an antipsychotic drug dose chlorpromazine in patients with psychotic symptoms. That is ensured by the results of genotyping using polymorphic markers of CYP1A2 genes to calculate the resultant rate change biotransformation of chlorpromazine (parameter P) by formula

,

where W_g is the number of CYP1A2 gene polymorphisms (main pathway biotransformation of chlorpromazine); A_i – change of speed biotransformation of chlorpromazine depending on the genotype for each polymorphic marker of the CYP1A2 gene. If change is defined as speed deviation biotransformation of chlorpromazine by 50 % and higher, replacement of the drug is recommended. If change is defined as deceleration of speed biotransformation of chlorpromazine less than by 50 %, dose reduction is recommended. At change, defined as speed acceleration biotransformation of chlorpromazine more than by 50 %, dose increase is recommended.

EFFECT: use of this method enables individual dose selection chlorpromazine, determining degree of manifestation of deviation of its speed biotransformation depending on the genotype for each polymorphic marker of the CYP1A2 gene.

1 cl, 1 tbl